Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 02, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share buyback transaction:
- Shares Purchased: 1,350,000 ordinary shares of 25 pence each.
- Purchase Price: 1,122.98 pence per share.
- Treasury Shares Held: 484,194,158 shares (representing 8.94% of total voting rights).
- Shares in Issue: 5,417,396,050 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 1,350,000 shares purchased on April 02, 2008. Consequently, the number of shares held in Treasury has been updated to reflect this transaction.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Key Facts for Investor Verification
- Verify the total cost of the buyback by multiplying 1,350,000 shares by 1,122.98 pence.
- Confirm the updated total voting rights denominator (5,417,396,050 shares) for regulatory disclosure thresholds.
- Note that 8.94% of voting rights are currently held in Treasury and do not carry voting rights.
- Check subsequent filings for broader financial performance, as this document is limited to the share repurchase event.